Parathyroid hormone alleviates non-alcoholic liver steatosis via activating the hepatic cAMP/PKA/CREB pathway

Parathyroid hormone alleviates non-alcoholic liver steatosis via activating the hepatic cAMP/PKA/CREB pathway

Non-alcoholic fatty liver disease (NAFLD), hallmarked by liver steatosis, is becoming a global concern, but effective and safe drugs for NAFLD are still lacking at present. Parathyroid hormone (PTH), the only FDA-approved anabolic treatment for osteoporosis, is important in calcium-phosphate homeost...

Full description

Bibliographic Details
Main Authors: Xu Feng, Ye Xiao, Qi Guo, Hui Peng, Hai-Yan Zhou, Jian-Ping Wang, Zhu-Ying Xia
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-08-01
Series:Frontiers in Endocrinology
Subjects:
parathyroid hormone
non-alcoholic liver steatosis
therapeutics
PTH1R
PKA/CREB pathway
Online Access:https://www.frontiersin.org/articles/10.3389/fendo.2022.899731/full

Internet

https://www.frontiersin.org/articles/10.3389/fendo.2022.899731/full

Similar Items